Screening mammograms, often associated with false-positive results in breast cancer-free women, may indicate underlying pathology that still could result in breast cancer, researchers said.
Screening mammograms, often associated with false-positive results in breast cancer-free women, may indicate underlying pathology that still could result in breast cancer, according to a study published today in the Journal of the National Cancer Institute.
It was not known if women whose tests show findings that lead to a false-positive may be at higher risk of developing breast cancer than women who do not test false-positive. After a diagnostic work-up eliminates a cancer diagnosis, the women are encouraged to continue with routine screening, but they may be reluctant to do so.
To evaluate the risk of breast cancer and ductal carcinoma in situ in women between the ages of 50 to 69 who had received false-positive mammography results, researchers from the University of Copenhagen gathered data from a long-standing Danish population-based screening mammography program that took place from 1991 to 2005.
The researchers found that women with false-positive results had a relative risk of breast cancer that was significantly higher than those who tested negative, even as long as six years after the initial screening.
In comparing women who tested negative with those who received false-positive results, the researchers found that the negative-finding women had an absolute cancer rate of 339/100,000 person-years at risk, while those with false-positive results had an absolute cancer risk of 583/100,000 person years at risk. Person-years is defined as the product of the number of years times the number of members of a population who have been affected by a certain condition.
“Based on the findings in this study, it may be beneficial to actively encourage women with false-positive tests to continue to attend regular screening,” the researchers concluded.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.